



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 94605

TO: Dwayne C Jones
Location: mail 2D01; room 2D07
Art Unit: 1614
Monday, June 02, 2003

Case Serial Number: 038135

From: Barb O'Bryen
Location: Biotech-Chem Library
CM1-6A05
Phone: 308-4291 *BOB*

barbara.obryen@uspto.gov

Search Notes

Dwayne,

The structure of claim 64 is too broad to search.

Claim 69 doesn't make sense. It states "...at least one R of R1, R2, and R3 is substituted or unsubstituted aryl and the R is selected from: mono, di, or tri methyl, methoxy, halo, ..." Since there is no plain "R" in the structure, I interpreted this to mean that whichever of R1, R2, R3 was aryl also had to meet the definitions of "the R". However, most of the things listed in the definition of "the R" are *not* aryls. I searched only claim 62 and the circled compounds of claims 67 and 70.

Barb

Hand only please

94605
SEARCH REQUEST FORM

Access DB# _____

Scientific and Technical Information Center

Requester's Full Name: Dwayne C. Jones Examining #: 71991 Date: 21 MAY 03
Art Unit: 614 Phone Number 30 8-164 Serial Number: 101038
Mail Box and Bldg/Room Location: 2001 CMS Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: see attached sheet
Inventors (please provide full names): _____

Earliest Priority Filing Date: 27 OCT 1999

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

20 of 12 6,455,571 { 11 of 22 (3) Please search claims 62, 64 and 69
5 of 42 2 16 of 23 (3) and the circled species of claims 67+70.
6 of 42 W4 99/16437 5,475,092 (3) 22 of 23 (1)
9 of 42 ? 12, 2nd claim 65-731.
26 of 42 list that the variable of
6,123,936 (31 of 42) ? R cell of R₁, R₂, R₃ is
6,423,690 ? = "... However there is no
6,231,285 (40 of 42) antecedent basis for the
9,593,268 ? variable of R. The only variables defined
5 of 23 (1) ? in claim 63 are R₁, R₂, R₃
5,478,115 (5 of 23) (2) look at 112, 1st W4 2 enable
9 of 23 or
SOP

STAFF USE ONLY

Searcher: <u>6073</u>	Type of Search	Vendors and cost where applicable
Searcher Phone #: _____	NA Sequence (#) _____	STN _____
Searcher Location: _____	AA Sequence (#) _____	Dialog _____
Date Searcher Picked Up: _____	Structure (#) _____	Questel/Orbit _____
Date Completed: <u>6-2-03</u>	Bibliographic _____	Dr.Link _____
Searcher Prep & Review Time: _____	Litigation _____	Lexis/Nexis _____
Clerical Prep Time: _____	Fulltext _____	Sequence Systems _____
Online Time: _____	Patent Family _____	WWW/Internet _____
	Other _____	Other (specify) _____

PTO-1590 (8-01)

BEST AVAILABLE COPY

L4 1 ANSWERS CAPLUS COPYRIGHT 2003 ACS
IC ICM C12N005-00
ICS C07C213-00
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1, 9
TI Pharmaceutical compositions comprising **primary** N-hydroxylamines
ST hydroxylamine pharmaceutical oxidative damage redn; senescence delay
hydroxylamine pharmaceutical
IT Encephalomyelitis
(autoimmune, hydroxylamines prevention of myelin basic protein-induced,
in rats; pharmaceutical compns. comprising primary N-hydroxylamines)
IT Drug delivery systems
(capsules; pharmaceutical compns. comprising primary N-hydroxylamines)
IT Nitrones
RL: MSC (Miscellaneous)
(compn. free from; pharmaceutical compns. comprising primary
N-hydroxylamines)
IT Aging, animal
Cell aging
(delaying; pharmaceutical compns. comprising primary N-hydroxylamines)
IT Drug screening
(for agents reducing oxidative damage; pharmaceutical compns.
comprising primary N-hydroxylamines)
IT Learning
(hydroxylamines redn. of deficit in, in autoimmune mice; pharmaceutical
compns. comprising primary N-hydroxylamines)
IT Lipopolysaccharides
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(hydroxylamines redn. of inflammation caused by; pharmaceutical compns.
comprising primary N-hydroxylamines)
IT Autoimmune disease
(hydroxylamines redn. of learning deficit in mice with; pharmaceutical
compns. comprising primary N-hydroxylamines)
IT Cytokines
Interleukin 1.beta.
RL: ADV (Adverse effect, including toxicity); BOC (Biological occurrence);
BSU (Biological study, unclassified); BIOL (Biological study); OCCU
(Occurrence)
(hydroxylamines redn. of .beta.-amyloid-induced release of;
pharmaceutical compns. comprising primary N-hydroxylamines)
IT Drug delivery systems
(injections; pharmaceutical compns. comprising primary
N-hydroxylamines)
IT Drug delivery systems
(liqs.; pharmaceutical compns. comprising primary N-hydroxylamines)
IT Behavior
(locomotor, hydroxylamines redn. of A.beta.-amyloid peptide-induced
impairment of, in rats; pharmaceutical compns. comprising primary
N-hydroxylamines)
IT Body weight
(loss, hydroxylamines prevention of myelin basic protein-induced, in
rats; pharmaceutical compns. comprising primary N-hydroxylamines)
IT Drug delivery systems
(lotions; pharmaceutical compns. comprising primary N-hydroxylamines)
IT Nerve
(neuron, hydroxylamines redn. of A.beta.-amyloid peptide
(12-35)-induced loss of, in rats; pharmaceutical compns. comprising
primary N-hydroxylamines)
IT Cytoprotective agents
(neuroprotectants; pharmaceutical compns. comprising primary
N-hydroxylamines)

- IT Drug delivery systems
(ointments, creams; pharmaceutical compns. comprising primary N-hydroxylamines)
- IT Drug delivery systems
(ointments; pharmaceutical compns. comprising primary N-hydroxylamines)
- IT Drug delivery systems
(oral; pharmaceutical compns. comprising primary N-hydroxylamines)
- IT Anti-Alzheimer's agents
Anti-inflammatory agents
Anti-ischemic agents
Diagnosis
Drug delivery systems
(pharmaceutical compns. comprising primary N-hydroxylamines)
- IT Antioxidants
(pharmaceutical; pharmaceutical compns. comprising primary N-hydroxylamines)
- IT Amines, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(primary N-hydroxylamines; pharmaceutical compns. comprising primary N-hydroxylamines)
- IT Conformation
(protein, .beta.-pleated sheet, hydroxylamines inhibition of .beta.-amyloid peptide formation of; pharmaceutical compns. comprising primary N-hydroxylamines)
- IT Oxidative stress, biological
(redn. of damage from; pharmaceutical compns. comprising primary N-hydroxylamines)
- IT Learning
(spatial, disorder, hydroxylamines prevention of N-nitro-L-arginine-caused of, in rats; pharmaceutical compns. comprising primary N-hydroxylamines)
- IT Brain, disease
(stroke, treatment of; pharmaceutical compns. comprising primary N-hydroxylamines)
- IT Drug delivery systems
(tablets; pharmaceutical compns. comprising primary N-hydroxylamines)
- IT Amyloid
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(.beta.-, hydroxylamines inhibition of .beta.-pleated sheet formation by; pharmaceutical compns. comprising primary N-hydroxylamines)
- IT Interferons
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(.gamma., hydroxylamines redn. of inflammation caused by; pharmaceutical compns. comprising primary N-hydroxylamines)
- IT 541-15-1D, Carnitine, compds.
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compn. further comprising; pharmaceutical compns. comprising primary N-hydroxylamines)
- IT 25316-40-9, Adriamycin
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxylamines amelioration of oxidn.-caused side effects of anticancer therapy with; pharmaceutical compns. comprising primary N-hydroxylamines)
- IT 3376-24-7, .alpha.-Phenyl-N-tert-butylnitron
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(pharmaceutical compns. comprising primary N-hydroxylamines)
- IT 2211-64-5P, N-Cyclohexylhydroxylamine 5080-22-8P, N-

Isopropylhydroxylamine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(pharmaceutical compns. comprising primary N-hydroxylamines)

IT 593-77-1, N-Methylhydroxylamine 622-30-0, N-Benzylhydroxylamine
16649-50-6, N-tert-Butylhydroxylamine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical compns. comprising primary N-hydroxylamines)

IT 64-19-7, Acetic acid, reactions 79-46-9, 2-Nitropropane 25100-12-3,
N-Cyclohexylhydroxylamine hydrochloride

RL: RCT (Reactant); RACT (Reactant or reagent)

(pharmaceutical compns. comprising primary N-hydroxylamines)

IT 621-07-8 622-30-0D, N-(Benzyl)hydroxylamine, derivs. 624-81-7,
N-Ethylhydroxylamine 627-38-3 2912-93-8, N-sec-Butylhydroxylamine
2912-94-9 2912-95-0 2912-97-2 3545-78-6 4410-93-9 4901-28-4
5080-24-0 13782-57-5 14469-03-5 26228-72-8 27886-24-4 29072-73-9